Company: SHPH
Filing Date: 2025-01-21
Form Type: 8-K
Source: 0001493152-25-002945
Chunk: 0

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-21
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events.

On
January 21 2025, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “ Company”), issued a press release announcing
that it has achieved 25% enrollment in the initial randomized portion of its Phase 2 clinical trial of Ropidoxuridine for the
treatment of patients with glioblastoma.

The
Phase 2 trial design is to initially randomize 40 patients into two different dose levels, with 20 patients receiving 1,200 mg/day and
20 patients receiving 960 mg/day, to determine an optimal dose for use in glioblastoma patients. Once the optimal dose is identified,
14 additional patients will be enrolled at the optimal dose to reach statistical significance with the end-point demonstrating survival
as compared to historical controls. The Phase 2 clinical trial is being conducted on patients presenting with the most aggressive form
of brain tumors - IDH wild-type, methylation negative glioblastoma. This cohort of patients currently only have radiation as the
standard of care, with less than half of the patients surviving beyond 12 months after diagnosis.

A
copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Item
8.01, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to liabilities under that section, and shall not be deemed
to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Exchange
Act, regardless of any general incorporation language in such filings. This Current Report on Form 8-K will not be deemed an admission
as to the materiality of any information of the information contained in this Item 8.01, including Exhibit 99.1.

Forward-Looking
Statements

This
Current Report on Form 8-K contains “forward-looking statements” within the meaning of Section 21E of the Exchange Act and
the Private Securities Litigation Reform Act of 1995. Forward-looking statements may relate to statements concerning future results,
strategy and plans of the Company (including certain statements which may be identified by the use of the words “plans,”
“expects,” “does not expect,” “estimated,” “is expected,” “budget,” “scheduled,”